A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

[1]  M. Jadoul,et al.  KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. , 2022, Kidney international.

[2]  J. Kao,et al.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 , 2022, Hepatology International.

[3]  Y. Takikawa,et al.  Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection , 2022, Health science reports.

[4]  Mei-Hsuan Lee,et al.  Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan , 2021, Infectious Diseases and Therapy.

[5]  L. Jeng,et al.  Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection , 2021, Antimicrobial agents and chemotherapy.

[6]  Wei Zhao,et al.  Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients , 2021, Journal of medical virology.

[7]  M. Jadoul,et al.  HCV Can and Should Be Eliminated From Dialysis Units. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  A. Mangia,et al.  Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease , 2021, The American journal of gastroenterology.

[9]  Hsiu-Hsi Chen,et al.  Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Sise,et al.  Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[12]  J. Kao,et al.  Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment , 2021, Gut.

[13]  Shang-Jyh Hwang,et al.  Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C) , 2020, Gut.

[14]  H. Xiang,et al.  Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C , 2020, Medicine.

[15]  G. Shiha,et al.  The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease , 2020, International Urology and Nephrology.

[16]  R. Aggarwal,et al.  Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  R. Dhiman,et al.  Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[18]  E. Overton,et al.  Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality , 2020, Pathogens & immunity.

[19]  H. Yen,et al.  Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting , 2020, PloS one.

[20]  T. Berg,et al.  Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R) , 2020, Zeitschrift für Gastroenterologie.

[21]  L. Rostaing,et al.  Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. , 2020, Transplantation proceedings.

[22]  Y. S. Kim,et al.  Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study , 2020, The Korean journal of internal medicine.

[23]  E. Gane,et al.  Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. , 2020, The lancet. Gastroenterology & hepatology.

[24]  Ding‐Shinn Chen,et al.  Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis , 2020, Scientific Reports.

[25]  K. Gohel,et al.  Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center Study. , 2020, Transplantation proceedings.

[26]  Chun-Jen Liu,et al.  Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[27]  Nisha Gaur,et al.  Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. , 2020, Journal of clinical and experimental hepatology.

[28]  M. Khondoker,et al.  The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection , 2020 .

[29]  N. Hotta,et al.  The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study , 2020, Hepatology International.

[30]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[31]  R. Carvalho-Filho,et al.  HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. , 2020, Arquivos de gastroenterologia.

[32]  P. Rathi,et al.  COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS. , 2020, Arquivos de gastroenterologia.

[33]  Ding‐Shinn Chen,et al.  Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment , 2020, Journal of viral hepatitis.

[34]  A. Mercan-Stanciu,et al.  Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease , 2020, BMC Nephrology.

[35]  N. Luck,et al.  Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan , 2020, Gastroenterology and hepatology from bed to bench.

[36]  R. Chung,et al.  Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. , 2020, Kidney international.

[37]  T. Masaki,et al.  Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[38]  M. Hassany,et al.  Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[39]  H. El‐Serag,et al.  Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. , 2019, Antiviral research.

[40]  M. Persico,et al.  Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[41]  Y. Yılmaz,et al.  Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. , 2019, Revista da Associacao Medica Brasileira.

[42]  N. Gilani,et al.  Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial , 2019, BMC Nephrology.

[43]  Ding‐Shinn Chen,et al.  Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non‐cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis , 2019, Journal of gastroenterology and hepatology.

[44]  S. Markova,et al.  Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis. , 2019, Journal of Hepatology.

[45]  J. Mallolas,et al.  Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study , 2019, PloS one.

[46]  G. Shiha,et al.  Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients , 2019, International Urology and Nephrology.

[47]  A. Abbasi,et al.  Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen , 2019, Cureus.

[48]  U. Akarca,et al.  Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. , 2019, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[49]  M. Persico,et al.  Real‐life efficacy and safety of glecaprevir/pibrentasvir in HCV‐infected patients with chronic kidney disease , 2019, GastroHep.

[50]  M. Haberal,et al.  Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list , 2019, Hemodialysis international. International Symposium on Home Hemodialysis.

[51]  A. Więcek,et al.  Effectiveness and safety of sofosbuvir‐based therapy against chronic hepatitis C infection after successful kidney transplantation , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[52]  Aiperi Asanbek kyzy.  SP641TREATMENT OF CHRONIC VIRAL HEPATITIS "C" WITH SOFOSBUVIR-LEDIPASVIR IN PATIENTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE , 2019, Nephrology Dialysis Transplantation.

[53]  H. Mansour,et al.  SP138Egyptian Experience of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis , 2019, Nephrology Dialysis Transplantation.

[54]  H. Nomura,et al.  Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[55]  P. Messa,et al.  Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study , 2019, Transplant international : official journal of the European Society for Organ Transplantation.

[56]  N. Hotta,et al.  The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study , 2019, Alimentary pharmacology & therapeutics.

[57]  P. Messa,et al.  Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. , 2019, Kidney international.

[58]  F. Ateş,et al.  Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey. , 2019, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[59]  M. Kurosaki,et al.  Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection , 2019, Journal of Gastroenterology.

[60]  I. Sack,et al.  A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients , 2019, BMC Nephrology.

[61]  M. Haberal,et al.  Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients. , 2019, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[62]  M. Mekky,et al.  Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. , 2019, Clinics and research in hepatology and gastroenterology.

[63]  Myeong Jun Song,et al.  Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis , 2019, Gut and liver.

[64]  G. Ioannou,et al.  What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? , 2019, Gastroenterology.

[65]  Jianghua Chen,et al.  Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[66]  M. Said,et al.  Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort , 2018, Expert review of gastroenterology & hepatology.

[67]  K. Reddy,et al.  Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease , 2018, Kidney international reports.

[68]  A. Tsubota,et al.  Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study , 2018, Journal of gastroenterology and hepatology.

[69]  G. Gerken,et al.  Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function , 2018, Transplantation Direct.

[70]  S. Sarin,et al.  Generic sofosbuvir‐based direct‐acting antivirals in hepatitis C virus‐infected patients with chronic kidney disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[71]  M. Jadoul,et al.  Hepatitis C virus and the kidney , 2018, Nature Reviews Nephrology.

[72]  H. Nomura,et al.  Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real‐world cohort study focusing on chronic kidney disease , 2018, Antiviral research.

[73]  B. Kasiske,et al.  Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. , 2018, Kidney international.

[74]  D. Fliser,et al.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease , 2019, Nephrology and Dialysis.

[75]  Sunita Kumari,et al.  Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency , 2018, Journal of viral hepatitis.

[76]  M. Sabbatini,et al.  Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life , 2018, BioMed research international.

[77]  F. Sanai,et al.  High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[78]  M. Kurosaki,et al.  Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[79]  P. Angus,et al.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection , 2018, Hepatology.

[80]  M. Kurosaki,et al.  Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection , 2018, Journal of Gastroenterology.

[81]  S. Pungpapong,et al.  Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[82]  H. Adanir,et al.  Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience , 2018, SAGE open medicine.

[83]  J. Butterton,et al.  Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers , 2018, Journal of clinical pharmacology.

[84]  N. Prasad,et al.  Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center , 2018, Indian journal of nephrology.

[85]  B. Kirushnan,et al.  Sofosbuvir‐based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study , 2018, Nephrology.

[86]  R. Šenkeříková,et al.  Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort , 2018, Kidney and Blood Pressure Research.

[87]  C. Jorge,et al.  Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal. , 2018, Transplantation proceedings.

[88]  T. Box,et al.  Rationale for treatment of hepatitis C virus infection in end‐stage renal disease patients who are not kidney transplant candidates , 2018, Hemodialysis international. International Symposium on Home Hemodialysis.

[89]  J. Francis,et al.  Timing of hepatitis C virus infection treatment in kidney transplant candidates , 2018, Hemodialysis international. International Symposium on Home Hemodialysis.

[90]  S. Raju,et al.  Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study , 2018, Hemodialysis international. International Symposium on Home Hemodialysis.

[91]  Sourabh Sharma,et al.  Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients , 2018, Journal of transplantation.

[92]  Y. Chawla,et al.  Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease , 2018, Digestive Diseases and Sciences.

[93]  N. Prasad,et al.  Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation , 2017, Clinical kidney journal.

[94]  Y. Chawla,et al.  Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients , 2017, Nephrology.

[95]  R. Mehta,et al.  Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis , 2018, Indian Journal of Gastroenterology.

[96]  A. Tsubota,et al.  Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[97]  T. Kumagai,et al.  Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection , 2017, JGH open : an open access journal of gastroenterology and hepatology.

[98]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[99]  K. Reddy,et al.  Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study , 2017, Hepatology.

[100]  G. Ciancio,et al.  Transplantation of kidneys from hepatitis C‐positive donors into hepatitis C virus‐infected recipients followed by early initiation of direct acting antiviral therapy: a single‐center retrospective study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[101]  S. Pol,et al.  Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. , 2017, The lancet. Gastroenterology & hepatology.

[102]  A. Gasbarrini,et al.  Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[103]  T. Yokoo,et al.  Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis , 2017, Nephrology.

[104]  C. Fernández-Rodríguez,et al.  Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience , 2017, Journal of viral hepatitis.

[105]  G. Gerken,et al.  Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients , 2017, Transplantation.

[106]  S. Agarwal,et al.  Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen , 2017, Kidney international reports.

[107]  T. Fujikawa,et al.  Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study , 2017, Renal Replacement Therapy.

[108]  N. Luck,et al.  Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce. , 2017, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[109]  S. Abad,et al.  Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4 , 2017, American Journal of Nephrology.

[110]  M. Manns,et al.  Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection , 2016, Annals of Internal Medicine.

[111]  K. Chayama,et al.  Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan , 2017, Journal of Gastroenterology.

[112]  A. Ido,et al.  New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir , 2017, Journal of Gastroenterology.

[113]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[114]  Ryoichi Miyazaki,et al.  Effect and Safety of Daclatasvir‐Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b ‐Infected Patients on Hemodialysis , 2016, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[115]  M. Shujauddin,et al.  Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study , 2016 .

[116]  H. Ohdan,et al.  Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study , 2016, Journal of viral hepatitis.

[117]  K. Reddy,et al.  Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. , 2016, Gastroenterology.

[118]  T. Ishikawa,et al.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis , 2016, Journal of Gastroenterology.

[119]  F. Sato,et al.  Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C , 2016, Journal of Gastroenterology.

[120]  Nancy D Berkman,et al.  Grading the strength of a body of evidence when assessing health care interventions: an EPC update. , 2015, Journal of clinical epidemiology.

[121]  T. Hassanein,et al.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.

[122]  P. Messa,et al.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis , 2015, Digestive Diseases and Sciences.

[123]  K. Kalantar-Zadeh,et al.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans , 2015, Hepatology.

[124]  E. Schiff,et al.  Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. , 2015, Journal of hepatology.

[125]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[126]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[127]  A. Macleod.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[128]  Beverley Rader Lugo,et al.  Clinical Experience , 2009 .